Table II.
The genotype and allele frequencies of PRNCR1 polymorphisms in PCa patients and controls with benign prostatic hyperplasia.
| Polymorphisms | PCa, n (%) | Controls, n (%) | OR (95% CI) | P-value |
|---|---|---|---|---|
| rs13252298 A>G | ||||
| Codominant | ||||
| AA | 33 (18.6) | 25 (14.0) | 1.00 | – |
| AG | 107 (60.1) | 141 (78.8) | 0.57 (0.32–1.04) | 0.078 |
| GG | 38 (21.3) | 13 (7.2) | 2.21 (0.98–5.01) | 0.070 |
| Dominant | ||||
| AA | 33 (18.5) | 25 (14.0) | 1.00 | – |
| AG+GG | 145 (81.4) | 154 (86.0) | 0.71 (0.40–1.26) | 0.254 |
| Recessive | ||||
| AA+AG | 140 (78.7) | 167 (92.8) | 1.00 | – |
| GG | 38 (21.3) | 13 (7.2) | 3.49 (1.79–6.81) | 0.0001 |
| Allele | ||||
| A | 173 (48.6) | 191 (53.4) | 1.00 | – |
| G | 183 (51.4) | 167 (46.6) | 1.21 (0.90–1.62) | 0.231 |
| rs1456315 A>G | ||||
| AA | 30 (16.9) | 92 (51.1) | 1.00 | – |
| AG | 148 (83.1) | 88 (48.9) | 5.16 (3.16–8.41) | <0.0001 |
| GG | 0 (0.0) | 0 (0.0) | – | – |
| A | 208 (58.4) | 272 (75.6) | 1.00 | – |
| G | 148 (41.6) | 88 (24.4) | 2.20 (1.60–3.03) | <0.0001 |
| rs7841060 T>G | ||||
| TT | 29 (16.3) | 96 (53.3) | 1.00 | – |
| TG | 149 (83.7) | 84 (46.7) | 5.14 (3.15–8.37) | <0.0001 |
| GG | 0 (0.0) | 0 (0.0) | – | – |
| T | 207 (58.1) | 276 (76.6) | 1.00 | – |
| G | 149 (41.9) | 84 (23.4) | 2.37 (1.71–3.26) | <0.0001 |
| rs7007694 T>C | ||||
| TT | 150 (84.3) | 139 (77.2) | 1.00 | – |
| TC | 28 (15.7) | 41 (22.8) | 0.63 (0.37–1.08) | 0.108 |
| CC | 0 (0.0) | 0 (0.0) | – | – |
| T | 328 (92.1) | 319 (88.6) | 1.00 | – |
| C | 28 (7.9) | 41 (11.4) | 0.66 (0.40–1.10) | 0.128 |
PCa, prostate cancer; PRNCR1, prostate cancer-associated non-coding RNA 1; OR, odds ratio; CI, confidence interval.